Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Gains from Sales and Divestitures (2022 - 2024)

Historic Gains from Sales and Divestitures for BioRestorative Therapies (BRTX) over the last 4 years, with Q4 2024 value amounting to $97827.0.

  • BioRestorative Therapies' Gains from Sales and Divestitures fell 597.45% to $97827.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $97827.0, marking a year-over-year decrease of 597.45%. This contributed to the annual value of $97827.0 for FY2024, which is 597.45% down from last year.
  • Per BioRestorative Therapies' latest filing, its Gains from Sales and Divestitures stood at $97827.0 for Q4 2024, which was down 597.45% from $97827.0 recorded in Q3 2024.
  • Over the past 5 years, BioRestorative Therapies' Gains from Sales and Divestitures peaked at $110270.0 during Q3 2022, and registered a low of $97827.0 during Q1 2024.
  • Its 3-year average for Gains from Sales and Divestitures is $102180.2, with a median of $104043.0 in 2023.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first dropped by 0.86% in 2023, then plummeted by 597.45% in 2024.
  • BioRestorative Therapies' Gains from Sales and Divestitures (Quarter) stood at $110270.0 in 2022, then fell by 5.65% to $104043.0 in 2023, then dropped by 5.97% to $97827.0 in 2024.
  • Its last three reported values are $97827.0 in Q4 2024, $97827.0 for Q3 2024, and $97827.0 during Q2 2024.